New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) For Antifungal Prophylaxis In Certain High Risk Patients
Schering-Plough Corporation (NYSE: SGP) reported that its antifungal agent NOXAFIL(R) (posaconazole) Oral Suspension received an A-1 recommendation(1) (highest rating) for the prevention of invasive Aspergillus infections in certain high- risk patients in the latest Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America (IDSA) released this month. (Source: Infectious Diseases / Bacteria / Viruses News From Medical News Today)
Teaching Public Health to First Year Medical StudentsTeaching Public Health to First Year Medical Students
How is public health being taught to medical school students in the United States? Are different educational models being used? Journal of Community Health (Source: Medscape Today Headlines)div id=medwormpbiMedWorm Sponsor Message:/i/b Have a look at a href=http://www.thepsychologydaily.comThe Psychology Daily/a, the new psychology portal powered by MedWorm, with all the latest psychology news and research updated daily./p/div
